{"filing":{"accession_number":"0001171843-26-005317","cik":"0001626971","ticker":"CRVS","company_name":"Corvus Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"f8k_080626.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1626971/000117184326005317/f8k_080626.htm"},"events":[{"id":25477,"run_id":23128,"accession_number":"0001171843-26-005317","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a clear earnings release disclosing Corvus Pharmaceuticals' financial results for Q2 2026 (three and six months ended June 30, 2026), including net loss of $18.0 million for Q2 2026, R\u0026D expenses of $16.0 million, and cash position of $215.2 million as of June 30, 2026. The press release is furnished as Exhibit 99.1 and filed under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings releases. The disclosure includes both financial results and a business update on clinical trial progress, which is typical for clinical-stage biopharmaceutical companies.","company_name":"Corvus Pharmaceuticals, Inc.","ticker":"CRVS","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26316,"accession_number":"0001171843-26-005317","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release disclosing Corvus Pharmaceuticals' financial results for Q2 2026 (three and six months ended June 30, 2026), including net loss of $18.0 million for Q2 2026, R\u0026D expenses of $16.0 million, and cash position of $215.2 million as of June 30, 2026. The press release is furnished as Exhibit 99.1 and filed under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings releases. The disclosure includes both financial results and a business update on clinical trial progress, which is typical for clinical-stage biopharmaceutical companies.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:48:01.633960+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26316,"accession_number":"0001171843-26-005317","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release disclosing Corvus Pharmaceuticals' financial results for Q2 2026 (three and six months ended June 30, 2026), including net loss of $18.0 million for Q2 2026, R\u0026D expenses of $16.0 million, and cash position of $215.2 million as of June 30, 2026. The press release is furnished as Exhibit 99.1 and filed under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings releases. The disclosure includes both financial results and a business update on clinical trial progress, which is typical for clinical-stage biopharmaceutical companies.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:48:01.633960+00:00","company_name":"Corvus Pharmaceuticals, Inc.","ticker":"CRVS","filing_date":"2026-08-06"}]}